{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:00:04Z","timestamp":1782331204119,"version":"3.54.5"},"publisher-location":"Chichester, UK","reference-count":40,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005088.pub2","type":"reference-entry","created":{"date-parts":[[2008,10,8]],"date-time":"2008-10-08T21:07:07Z","timestamp":1223500027000},"source":"Crossref","is-referenced-by-count":69,"title":["Bisphosphonate therapy for osteogenesis imperfecta"],"prefix":"10.1002","author":[{"given":"Carrie A","family":"Phillipi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Remmington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,8]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005088.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"issue":"8","key":"10.1002\/14651858.CD005088.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1359\/JBMR.050312","article-title":"Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta","volume":"20","author":"Gatti","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.","volume":"21","author":"Chevrel","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub2-BIB5|cit4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/JPEM.2005.18.1.43","article-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta","volume":"18","author":"Dimeglio","year":"2005","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub2-BIB4|cit5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"Suppl","key":"10.1002\/14651858.CD005088.pub2-BIB7|cit7","first-page":"1043","article-title":"Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]","volume":"20","author":"Glorieux","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD005088.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9419","key":"10.1002\/14651858.CD005088.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functiona outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD005088.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"Journal of Pediatric Orthopaedics"},{"issue":"3","key":"10.1002\/14651858.CD005088.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","article-title":"Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis","volume":"129","author":"Antoniazzi","year":"1996","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","article-title":"Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta","volume":"35","author":"DiMeglio","year":"2004","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0003-9993(98)90207-6","article-title":"Effect of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta","volume":"79","author":"Gerber","year":"1998","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"216","key":"10.1002\/14651858.CD005088.pub2-BIB15|cit15","first-page":"228","article-title":"Phyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta","volume":"Jul-Aug","author":"Granda","year":"1977","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"7","key":"10.1002\/14651858.CD005088.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD005088.pub2-BIB17|cit17","unstructured":"A study to assess the effectiveness of teriparatide (FORTEO) for increasing bone mass and improving bone structure in adults affected with OI.Study ID numbers: IBMD-OI.ClinicalTrials.gov identifier NCT00063479. Ongoing study"},{"key":"10.1002\/14651858.CD005088.pub2-BIB18|cit18","unstructured":"Bisphosphonate treatment of OI.Study ID numbers: CZOL446H2202.ClinicalTrials.gov identifier NCT00063479. Ongoing study"},{"issue":"9041","key":"10.1002\/14651858.CD005088.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD005088.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jmg.28.7.433","article-title":"Osteogenesis imperfecta: translation of mutation to phenotype","volume":"28","author":"Byers","year":"1991","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD005088.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.me.43.020192.001413","article-title":"Osteogenesis imperfecta","volume":"43","author":"Byers","year":"1992","journal-title":"Annual Review of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005088.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00008480-200012000-00016","article-title":"Osteogenesis imperfecta: perspectives and opportunities","volume":"12","author":"Byers","year":"2000","journal-title":"Current Opinion in Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD005088.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200208000-00003","article-title":"Advances in Osteogenesis Imperfecta","volume":"401","author":"Cole","year":"2002","journal-title":"Clinical Orthopaedics and Related Research"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajmg.1320220205","article-title":"Lethal neonatal chondrodysplasias in the West of Scotland 1970-1983 with a description of a thanatophoric, dysplasialike, autosomal recessive disorder, Glasgow variant","volume":"22","author":"Connor","year":"1985","journal-title":"American Journal of Medical Genetics"},{"issue":"1","key":"10.1002\/14651858.CD005088.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005088.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [abstract]","volume":"96","author":"Fisher","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"14","key":"10.1002\/14651858.CD005088.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD005088.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: a new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7414","key":"10.1002\/14651858.CD005088.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7303","key":"10.1002\/14651858.CD005088.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD005088.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/000348940211101014","article-title":"Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey","volume":"111","author":"Kuurila","year":"2002","journal-title":"The Annals of Otology, Rhinology, and Laryngology"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005088.pub2-BIB34|cit34","unstructured":"Osteogenesis Imperfecta Foundation Facts about Osteogenesis Imperfecta www.oif.org"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajmg.1320590218","article-title":"Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta","volume":"59","author":"Orioli","year":"1995","journal-title":"American Journal of Medical Genetics"},{"issue":"9","key":"10.1002\/14651858.CD005088.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD005088.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD005088.pub2-BIB38|cit38","unstructured":"Steiner RD Pepin MG Byers PH Gene Reviews; Osteogenesis Imperfecta www.genetests.org"},{"issue":"9","key":"10.1002\/14651858.CD005088.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/adc.2006.093997","article-title":"Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis","volume":"91","author":"Thornton","year":"2006","journal-title":"Archives of Disease in Childhood"},{"issue":"5","key":"10.1002\/14651858.CD005088.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005088.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:44:45Z","timestamp":1628531085000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005088.pub2"}},"subtitle":[],"editor":[{"given":"Carrie A","family":"Phillipi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,10,8]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005088.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.721156485.793509193","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2008,10,8]]}}}